item management s discussion and analysis of financial condition and results of operations general the following discussion and analysis should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this report 
the following table sets forth  for all periods indicated  the percentage relationship that items in the company s statements of operations bear to net sales 
year ended april  net sales cost of sales gross profit selling  general administrative expense research development costs contract research income interest expense interest income and other total expenses income before tax provision income tax provision net income results of operations years ended april  and for the fiscal year ended april  fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the successful introduction of new generic products into the marketplace in fiscal and increased shipments to the company s existing customers as well as several new customers in fiscal the company s high levels of customer service and the ability to produce high quality products has also contributed to our results 
some of the leading products that were included in this mix for the past year were albuterol sulfate inhalation solution and syrup  sulfamethoxazole  trimethoprim  lactulose solution  promethazine dm  as well as promethazine with codeine  lidocaine oral syrup  and several other prescription products 
no one product accounted for or more of total sales 
generic pharmaceutical products  which include private label contract manufacturing  had net sales for fiscal of  an increase of  or  compared to  in fiscal the increase resulted from increased demand and the successful introduction of new generic products into the marketplace in fiscal health care products division  which markets the company s branded products  for fiscal and had net sales of  and  respectively 
net sales increased by  or 
cost of sales  as a percentage of net sales  decreased from for fiscal to for fiscal 
table of contents labor and overhead costs decreased approximately 
units shipped increased and the average unit selling price increased 
in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as market conditions change 
if one or more other generic pharmaceutical manufacturers significantly reduce their prices in an effort to gain market share or the supplier of active ingredients increases their prices  the company s profitability could be adversely affected 
selling  general and administrative expenses  as percentage of net sales  increased from to  an increase of  the increase from  for fiscal to  for fiscal resulted principally from increased sales commissions  freight expenditures  and professional fees 
the company incurred a non cash pre tax charge for options granted in and to a consultant who is a director of the company in the amount of  for fiscal this pre tax charge was based  in part  on the market value of the company s stock  which appreciated substantially over the respective reporting periods 
research and development costs increased to  or for fiscal from  for fiscal as a result of  among other things  expenses associated with the filing of abbreviated new drug applications andas with the fda as well as development of non anda products for the company 
certain of the company s pharmaceutical products do not require prior approval before marketing 
however  many products which the company introduced and intends to introduce under its product development program will require prior fda approval using the anda procedure before they can be manufactured and marketed 
such products include products to be manufactured in the company s sterile facility 
net income increased or  to  for fiscal from net income of  for fiscal  as a result of the factors noted above 
results of operations years ended april  and for fiscal year ended april  fiscal  net sales increased by  or to  from  for the fiscal year ended april  fiscal 
the increase was primarily the result of the increased shipments to the company s existing customers as well as several new customers in fiscal generic pharmaceutical products  which include private label contract manufacturing  had net sales for fiscal of  an increase of  or  compared to the fiscal respective period 
no one product accounted for sales of or more of total sales for each respective period 
health care products division  which markets the company s branded products  for fiscal and  had net sales of  and  respectively 
sales of health care products division increased modestly as a result of a mild cold and flu season 
cost of sales  as a percentage of net sales  increased from for fiscal to for fiscal in the generic drug industry  certain products may contribute significantly to a company s gross profit 
the gross profit on these products may change as 
table of contents market conditions change 
in the aggregate  the costs  as a percentage of sales  for materials increased and labor and overhead decreased 
units shipped increased and the average unit selling price increased which resulted from changes in product mix and competitive conditions 
if one or more other generic pharmaceutical manufacturers significantly reduce their prices in an effort to gain market share  the company s profitability could be adversely affected 
selling  general and administrative expenses  as percentage of net sales decreased from  to  or decreased to  for fiscal from  for fiscal  a decrease of  resulting principally from reduced advertising and promotion expenditures for the health care products division as a result of a mild cold and flu season 
research and development costs increased to  or of sales for fiscal from  or of sales for fiscal as a result of  among other things  expenses associated with the filing of abbreviated new drug applications andas with the fda as well as development of new products for the company s health care products division 
many of the company s pharmaceutical products do not require prior approval before marketing 
however  certain products which the company introduced and intends to introduce under its product development program will require prior fda approval using the anda procedure before they can be manufactured and marketed 
such products include products to be manufactured in the company s sterile facility 
net income increased to  for fiscal from net income of  for fiscal  as a result of the factors noted above 

table of contents liquidity and capital resources the company s operations are historically financed principally by cash flow from operations and bank borrowing 
at april  and april   working capital was approximately  and  respectively 
cash flows from operating activities were approximately  which was the result principally of net income and depreciation of  cash flows used in investing activities were approximately  from operating activities funds and was principally payments for fixed assets acquired 
cash flows from the exercise of stock options were  accounts payable increased from  for fiscal to  for fiscal due principally to a greater level of business during the fourth fiscal quarter and the aging of days of payables increasing 
accrued expenses increased from  for fiscal to  for fiscal as a result of the increased levels of business 
on october  the company replaced its existing credit facility with a new three year  revolving credit facility 
the revolving credit facility bears interest at a rate elected by the company equal to the prime rate or the libor rate plus 
loans are collateralized by inventory  accounts receivable and other assets 
the agreement contains covenants with respect to working capital  net worth and certain ratios  as well as other covenants and prohibits the payment of cash dividends 
at april  there were no borrowings under the credit facility 
in march  the company purchased for  a warehouse which it previously leased 
on july  the company entered into a definitive agreement with certain accredited investors with respect to the private placement of  shares of its 
table of contents common stock at a purchase price of per share  for net proceeds of approximately million 
in addition  the private placement investors have a right to purchase up to an additional  shares of common stock at per share 
the additional investment rights are exercisable upon closing and will expire trading days after the effectiveness of a registration statement for the resale of the common stock 
the net proceeds will be used mainly for the funding of future acquisitions  research and development and for general corporate purposes 
the company believes that its financial resources consisting of current working capital  anticipated future operating revenue and its credit line will be sufficient to enable it to meet its working capital requirements for at least the next months 
in may  the company announced a stock buy back program under which the board of directors authorized the purchase of up to  of its common stock 
in august  the company increased the stock buy back program to an aggregate of  as of april   the company had purchased  shares at a cost of  new accounting pronouncements in april  the financial accounting standards board issued sfas no 
 rescission of fasb statements no 
  and  amendment of fasb statement no 
 and technical corrections 
sfas no 
rescinds the requirement that all gains and losses from extinguishment of debt be classified as an extraordinary item 
additionally  sfas no 
requires that certain lease modifications that have economic effects similar to sale leaseback transactions be accounted for in the same manner as sale leaseback transactions 
sfas no 
is effective for the company beginning in  and the effect of adoption is not expected to have a material impact on the financial statements 
in june  the fasb issued sfas no 
 accounting for costs associated with exit and disposal activities 
this statement revises the accounting for exit and disposal activities under emerging issues task force issue no 
 liability recognition for certain employee termination benefits and other costs to exit an activity 
specifically  sfas requires that companies record the costs to exit an activity or dispose of long lived assets when those costs are incurred 
sfas requires that the measurement of the liability be at fair value 
the provisions of sfas are effective prospectively for exit or disposal activities initiated after december  and will impact any exit or disposal activities initiated after such date 
in december  the fasb issued sfas no 
 accounting for stock based compensation transition and disclosure 
this statement amends sfas no 
 accounting for stock based compensation  to provide alternative methods of transition for an entity that changes to the fair value method of accounting for stock based employee compensation 
in addition  sfas amends the disclosure provisions of sfas to require expanded and more prominent disclosures in annual financial statements about the method of accounting for stock based compensation and the proforma effect on reported results of applying the fair value method for entities that use the intrinsic value method 
the proforma disclosures are also required to be displayed prominently in interim financial statements 
the company does not intend to change to the fair value method of accounting and has included the disclosure requirements of sfas in the accompanying financial statements 
in november  the fasb issued interpretation no 
 guarantor s accounting and disclosures requirements for guarantees  including indirect guarantees of indebtedness of others fin 
fin requires that upon issuance of a guarantee  the guarantor must recognize a liability for the fair value of the obligation it assumes under that guarantee 
fin is effective on a prospective basis to guarantees issued or modified after december   but has certain disclosure requirements effective for financial statements of interim or annual periods ending after december  the company does not currently have any guarantees 
the company does not anticipate that the adoption of the disclosure requirements of fin will have a material effect on its financial position or results of operations 
in january  the fasb issued fasb interpretation fin  consolidation of variable interest entities 
fin clarifies the application of accounting research bulletin  consolidated financial statements  for certain entities that do not have sufficient equity at risk for the entity to finance its activities without additional subordinated financial support from other parties or in which equity investors do not have the characteristics of a controlling financial interest variable interest entities 
variable interest entities within the scope of fin will be required to be consolidated by their primary beneficiary 
the primary beneficiary of a variable interest entity is determined to be the party that absorbs a majority of the entity s expected losses  receives a majority of its expected returns  or both 
fin applies immediately to variable interest entities created after january   and to variable interest entities in which an enterprise obtains an interest after that date 
it applies in the first fiscal year or interim period beginning after june   to variable interest entities in which an enterprise holds a variable interest that it acquired before february  the company is in the process of determining what impact  if any  the adoption of the provisions of fin will have upon its financial condition or results of operations 
management does not anticipate that adoption of these standards will have a material impact on the company s financial position or results of operations 
revenue recognition revenue is recognized for product sales upon shipment to the customer and when estimates of discounts  rebates  promotional adjustments  price adjustments  returns  chargebacks  and other potential adjustments are reasonably determinable  collection is reasonably assured and the company has no further performance obligations 
these estimates are presented in the financial statements as reductions to net revenues and accounts receivable 
estimated sales returns  allowances and discounts are provided for 
contract research income is recognized as work is completed and billable costs are incurred 
in certain cases  contract research income is based on attainment of designated milestones 
returns consistent with industry practice  the company maintains a return policy that allows its customers to return product within a specified period prior to expiration 
the company s estimate for returns is based upon its historical experience with actual returns 
while such experience has allowed for reasonable estimations in the past  history may not always be an accurate indicator of future returns 
the company continually monitors its estimates for returns and makes adjustments when it believes that actual product returns may differ from the established accruals 
chargebacks the company markets products directly to wholesalers  distributors  retail pharmacy chains  mail order pharmacies and group purchasing organizations 
the company also markets products indirectly to independent pharmacies  managed care organizations  hospitals  nursing homes and pharmacy benefit management companies  collectively referred to as indirect customers 
the company enters into agreements with its indirect customers and enters into agreements with its wholesalers to establish contract pricing for certain products 
indirect customers then independently select a wholesaler from which to actually purchase the products at these contracted prices 
the company will provide credit to the wholesaler for any difference between the contracted price and the wholesaler s invoice price 
such credit is called a chargeback 
the estimate for chargebacks is based on expected and historical sell through levels by its wholesaler customers to contracted customers 
the company continually monitors its provision for chargebacks and makes adjustments when it believes that actual chargebacks may differ from established estimates 
item a 
quantitative and qualitative disclosures about market risk the disclosure required by this item is not material to the company because the company does not currently have any exposure to market rate sensitive instruments  as defined in this item 

table of contents 
